Testing immune cell trogocytosis to predict CAR-T response in lymphoma
Tests immune cell trogocytosis as a possible predictor in adults with diffuse large B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
Key facts
- Where
- Montpellier, FranceSee the 2 sites
Where in France
- Clinical hematology department, University HospitalMontpellier, FranceTaking people
- Clinical Investigation Center, University HospitalMontpellier, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Montpellier
- Trial code
- NCT06352242
- Record updated
- 22 June 2026
- Original description
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic "signature" of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL.Read full original descriptionShow less
La Trogocytose Est-elle un Marqueur prédictif de la réponse Aux Cellules CAR-T Dans Les Lymphomes Diffus à Grandes Cellules B ?
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic "signature" of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL.
Inclusion: For patients; Patient who has given free and informed consent in writing for inclusion in the non-interventional CART-BANK protocol, and orally for the CARTROG protocol,; Patients over 18 years of age at the time of inclusion,; Diagnosis of LDGCB,; Decision to treat with anti-CD19 CAR-T cells,; Patient affiliated to or benefiting from a social security scheme; For healthy volunteers:; Given free and informed oral consent for inclusion in the CARTROG protocol,; Donor between 18 and 70 years of age at the time of inclusion,; No history of solid cancer or hematological malignancy,; No known chronic pathology (e.g. hypertension, diabetes, etc.) and no daily treatment,; No surgical treatment within the last 6 months.
Exclusion: Patients who do not meet all the inclusion criteria,; Pregnant or breast-feeding patient,; Patient unable to follow the procedures and/or frequency of visits planned in the trial, for psychological, family, social or geographical reasons,; Patient unable to consent freely to inclusion, under guardianship, curatorship or safeguard of justice.